Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving skin clearance in patients with moderate-to-severe plaque psoriasis after 12 weeks.
Co-primary endpoints were 90% or more improvement from Baseline Psoriasis Area and Severity Index (PASI 90) and Investigator’s Global Assessment (IGA) mod 2011 0/1 (clear or almost clear) response rates at Week 12. The data showed that 66.5% and 72.3% of patients treated with Cosentyx achieved a PASI90 score after 12 weeks and 16 weeks respectively, compared to 47.9% and 55.4% with Stelara.
In addition, 38.1% of those taking Cosentyx achieved a PASI100 score at week 12, compared to just 20.1% with Stelara.
Cosentyx, which, according to Novartis, is the first and only fully human IL-17A inhibitor approved to treat psoriasis, psoriatic arthritis and ankylosing spondylitis, works by inhibiting the IL-17A cytokine which is key to the pathogenesis of these conditions.
“These data add to the robust body of evidence supporting the use of Cosentyx to treat moderate to severe plaque psoriasis,” commented Mark Lebwohl, Managing Director and Chairman of the Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York City. “With these findings, clinicians can have even greater confidence including Cosentyx in their treatment plans.”
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …